NCT03440424View on ClinicalTrials.gov

Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 26, 2018

Primary Completion Date

April 23, 2018

Study Completion Date

April 23, 2018

Conditions

Hepatic Impairment

Interventions

DRUG

Lemborexant

oral tablet

Trial Locations (2)

32809

Orlando Clinical Research Center, Orlando

33014

Clinical Pharmacology of Miami, LLC, Miami

All Listed Sponsors

collaborator

Purdue Pharma LP

INDUSTRY

lead

Eisai Inc.

INDUSTRY

NCT03440424 - Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects | Biotech Hunter | Biotech Hunter